Macrophage immunometabolism in glioblastoma: from microglial reprogramming to B cell dysfunction
- 1Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University
- 2Weinberg College of Arts and Sciences, Northwestern University
- 3Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
Abstract
Glioblastoma (GBM) is an aggressive primary brain tumor whose progression and resistance to therapy are driven not only by malignant cells but also by extensive metabolic and immunological remodeling of the tumor microenvironment (TME). Among the most abundant immune populations within the GBM TME are tumor-associated macrophages (TAMs), including resident microglia and infiltrating monocyte-derived macrophages. Under physiological conditions, microglia preserve central nervous system (CNS) homeostasis through immune surveillance, phagocytosis, synaptic remodeling, and metabolic regulation. However, exposure to tumor-derived signals, hypoxia, and nutrient deprivation reprograms these cells toward predominantly immunosuppressive phenotypes that promote tumor growth, angiogenesis, immune evasion, and therapeutic resistance. Emerging evidence demonstrates that TAMs engage in extensive bidirectional communication with B cells, further shaping the immunosuppressive landscape of GBM. Macrophages regulate B-cell activation, survival, differentiation, and antigen presentation through cytokines, chemokines, growth factors, and direct cell-cell interactions, while B cells influence macrophage polarization through antibody production and inflammatory signaling. Simultaneously, metabolic competition within the TME, characterized by glucose depletion, lactate accumulation, and hypoxia, impairs B-cell effector functions, diminishes antigen presentation and humoral immunity, and promotes the development of regulatory B cells (Bregs), thereby reinforcing immune suppression and facilitating tumor progression. This review summarizes the physiological functions of microglia, the metabolic and functional reprogramming of tumor-associated myeloid populations in GBM, and the emerging evidence surrounding TAM–B-cell interactions. By integrating findings from GBM with mechanistic insights from other tumor and disease contexts, we examine how metabolic constraints within the TME could potentially influence macrophage–B-cell crosstalk. We propose this relationship as a novel and testable framework for understanding immune regulation in GBM, while distinguishing established GBM-specific mechanisms from pathways supported primarily by evidence in other disease settings. Finally, we discuss how macrophage immunometabolism and its potential intersection with B-cell function may represent areas for future investigation and therapeutic exploration in GBM.
Related
- A synthetic PGC1α co-activator reprograms microglial immunometabolism to preserve cone function in retinal degeneration
- Macrophage immunometabolism in osteoporosis: an emerging regulatory axis linking metabolic–polarization coupling to therapeutic targets
- Linoleic Acid-Lyso PG Axis promoting lipid droplet-mitochondria tethering by stabilizing Noncanonically Mitochondrial PPAR β/δ to Ameliorate Microglial Dysfunction in subarachnoid hemorrhage
- Inflammatory proteostasis reprogramming creates a lysosomal bottleneck for microglial aggregate clearance
- Forsythoside B attenuates neuropathic pain by suppressing USP7/HIF-1α-mediated microglial glycolytic reprogramming
BibTeX
@article{yu2026macrophage,
title = {{Macrophage immunometabolism in glioblastoma: from microglial reprogramming to B cell dysfunction}},
author = {Elizabeth Yu and Grace Jones and Catalina Lee-Chang},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1947853},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1947853/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Macrophage immunometabolism in glioblastoma: from microglial reprogramming to B cell dysfunction
AU - Elizabeth Yu
AU - Grace Jones
AU - Catalina Lee-Chang
PY - 2026
DA - 2026/10/26
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1947853
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1947853/full
AB - Glioblastoma (GBM) is an aggressive primary brain tumor whose progression and resistance to therapy are driven not only by malignant cells but also by extensive metabolic and immunological remodeling of the tumor microenvironment (TME). Among the most abundant immune populations within the GBM TME are tumor-associated macrophages (TAMs), including resident microglia and infiltrating monocyte-derived macrophages. Under physiological conditions, microglia preserve central nervous system (CNS) homeostasis through immune surveillance, phagocytosis, synaptic remodeling, and metabolic regulation. However, exposure to tumor-derived signals, hypoxia, and nutrient deprivation reprograms these cells toward predominantly immunosuppressive phenotypes that promote tumor growth, angiogenesis, immune evasion, and therapeutic resistance. Emerging evidence demonstrates that TAMs engage in extensive bidirectional communication with B cells, further shaping the immunosuppressive landscape of GBM. Macrophages regulate B-cell activation, survival, differentiation, and antigen presentation through cytokines, chemokines, growth factors, and direct cell-cell interactions, while B cells influence macrophage polarization through antibody production and inflammatory signaling. Simultaneously, metabolic competition within the TME, characterized by glucose depletion, lactate accumulation, and hypoxia, impairs B-cell effector functions, diminishes antigen presentation and humoral immunity, and promotes the development of regulatory B cells (Bregs), thereby reinforcing immune suppression and facilitating tumor progression. This review summarizes the physiological functions of microglia, the metabolic and functional reprogramming of tumor-associated myeloid populations in GBM, and the emerging evidence surrounding TAM–B-cell interactions. By integrating findings from GBM with mechanistic insights from other tumor and disease contexts, we examine how metabolic constraints within the TME could potentially influence macrophage–B-cell crosstalk. We propose this relationship as a novel and testable framework for understanding immune regulation in GBM, while distinguishing established GBM-specific mechanisms from pathways supported primarily by evidence in other disease settings. Finally, we discuss how macrophage immunometabolism and its potential intersection with B-cell function may represent areas for future investigation and therapeutic exploration in GBM.
SN - 1664-3224
ER -